None
Revised Financial Outlook and Investment Strategy:
-
revised its full-year 2025 guidance due to macroeconomic uncertainties, with an expected adjusted operating income range of
$5.7 to $6.1 billion compared to the previous range of
$6.3 to $6.7 billion.
- The revised outlook provides flexibility for increased investments in marketing, R&D, and technology, with a focus on improving brand superiority and driving long-term growth.
Increased Marketing and Media Investments:
- The company plans to step up its marketing investment to reach approximately
4.8% of sales in the mid-point of the guidance, representing a
30 bps increase from the previous guidance.
- The additional investment will be allocated towards media pressure to support product renovations and brand growth, while maintaining the overall marketing percentage of revenue at
4.5%.
North American Sales Dynamics and Market Trends:
- In North America,
expects second-quarter sales to be better than the first quarter, despite a plant closure lap and impacts from product reformulations and consumer reports.
- Growth is anticipated in categories like cream cheese (Philadelphia) and snacks due to improvements in ACCELERATE platforms and the resolution of competitive out-of-stock issues from 2024.
International and Emerging Market Growth:
- The company's international segment, excluding North America, is expected to accelerate further, contributing positively to overall sales growth in the second quarter.
- This improvement is driven by the implementation of brand growth systems and the completion of major product renovations, particularly in emerging markets.
Inflationary Pressures and COGS Impact:
- Kraft Heinz anticipates COGS inflation to increase to
5%, driven by significant increases in commodities like coffee and meat, and an estimated tariff impact of
150 to 200 bps on COGS in 2025.
- The company is mitigating these pressures through inventory management, alternative sourcing, and strategic mix adjustments, with pricing increases as a last resort.
Comments
No comments yet